ClinicalTrials.gg
RecruitingNCT06405074LIFU_TUDUpdated Nov 20, 2024

Low Intensity Focused Ultrasound for Tobacco Use Disorder: High Resolution Targeting of the Human Insula

An interventional study of low intensity focused ultrasound (LIFU) in Tobacco Use Disorder, sponsored by Washington D.C. Veterans Affairs Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-11-20.

Sponsored by Washington D.C. Veterans Affairs Medical Center · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 7 months after the study started (first participant enrolled Apr 2022, registered Nov 2023).
  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 799 studies in Tobacco Use Disorder with a site in United States — 75 open to participants now, 91 under way, 5 of them phase 3. Tobacco Use Disorder · United States.

Planned enrollment
507th of 736
44 · median 84
Started
2022
with 23 others
No phase
364 of 799
47 open now
Primary completion
2026-03
later than 4 of 90 live
Registered
725th of 799
by date

Among the 799 studies in Tobacco Use Disorder with a site in United States, this one is the 507th largest by planned enrollment of the 736 interventional ones that give a count, is one of 24 that started in 2022, is one of 364 with no phase, reaches primary completion later than 4 of the 90 other live ones, and was the 725th registered.

Tobacco Use Disorder

1,028 studies on the registry are indexed under Tobacco Use Disorder; 128 are open to participants now.

Browse Tobacco Use Disorder studies →

Open to participants now

75 of the 799 studies in Tobacco Use Disorder with a site in United States are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 95 Tobacco Use Disorder studies recruiting now, 42 (44%) set no upper age limit and 50 (53%) stop at 75 or younger; 6 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 799 studies in Tobacco Use Disorder with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to to inhibit the dorsal anterior insula (dAI) with low intensity focused ultrasound (LIFU) to determine the causal role for the dAI in smoking cue induced craving in individuals with tobacco use disorder (TUD); smoking cue induced craving is a clinically important behavior which has been associated with the severity of nicotine addiction. The main question[s] it aims to answer are:

  • the safety and tolerability of dAI LIFU compared to sham stimulation in individuals with TUD
  • the effects of LIFU vs sham to left dAI functional magnetic resonance imaging (fMRI) BOLD activity and craving in response to smoking cue exposure.

Participants will undergo anatomical MRI, neurological assessment, clinical assessment and patient query to assess the safety and tolerability of LIFU vs sham.

Participants will undergo functional magnetic resonance imaging where we will measure the effect of LIFU vs sham on 1) dAI blood-oxygen-level-dependent (BOLD) activation in response to smoking (compared to neutral) cue exposure and 2) cue-induced craving in individuals with TUD. Each participant will receive LIFU and sham stimulation.

Read the detailed description

Tobacco use disorder (TUD) remains the leading cause of preventable death in the world. Costs of smoking related illness in the United States totals more than $300 billion each year. The majority of adult cigarette smokers want to quit and more than half make an attempt but fewer than 1 in 10 smokers successfully quit at the end of 1 year. Rates of cigarette smoking are higher and cessation rates are lower in the veteran population in the United States compared to the nonveteran population. Noninvasive neuromodulation holds promise as a therapeutic approach to TUD as evidenced by the recent food and drug administration (FDA) clearance of deep transcranial magnetic stimulation (TMS) as such a treatment. One additional, emerging potential therapeutic is using low-intensity focused ultrasound (LIFU) to inhibit cortical and deep brain regions. The enormous potential of LIFU stems from the ability to focus ultrasound through the intact skull to a millimeter-sized focal spot size anywhere in the brain. This makes it a powerful alternative to both invasive neurosurgical procedures and other noninvasive brain stimulation techniques such as TMS that have limited spatial resolution and can only reach superficial areas of the brain. One promising target to treat TUD is the dorsal anterior insular cortex (dAI), a brain structure whose function is linked to the desire to smoke. The dAI is a part of the salience network (SN) that is involved in assigning significance and emotional value to stimuli and is consistently activated with exposure to smoking cues and craving. Remarkably, humans with damage to the insula were able to stop smoking easily and without experiencing cravings or relapse. As such, the insula is a promising target for reducing craving and use in individuals with TUD. Unfortunately, the dAI is small and lies deep within the lateral sulcus covered by the overlying opercula of the temporal lobe and is not accessible with conventional noninvasive neuromodulatory techniques. LIFU can selectively target the dAI and provides a potentially transformative method to reduce nicotine craving and addiction. The overall purpose of this proposal is to inhibit the dAI with LIFU to determine the causal role for the dAI in smoking cue induced craving which is a clinically important behavior which has been associated with the severity of nicotine addiction.

03

Conditions studied

  • Tobacco Use Disorder

Keywords

  • low intensity focused ultrasound
  • functional magnetic resonance imaging
  • insula
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female veterans aged 18-75 years
  2. Meet the Diagnostic and Statistical Manual, Fifth edition () criteria for current TUD (moderate to severe) as diagnosed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.
  3. Currently smoking > 10 cigarettes per day with no period of abstinence > 3 months in the last year
  4. Current use of tobacco in last year is limited to cigarettes
  5. Currently in Contemplation Stage of motivation for behavior change with respect to smoking as assessed by the University of Rhode Island Change Assessment Scale

Exclusion criteria

Exclusion Criteria:

  1. Not under current treatment for smoking cessation.
  2. No history of head injury, seizures, neurologic disorders including cerebrovascular disease, multiple sclerosis, or neurodegenerative diseases or major medical illness
  3. Current substance use disorder for a psychoactive substance (except nicotine)
  4. psychiatric disorder requiring current treatment
  5. Ferromagnetic implants or other for MRI
  6. Taking any psychotropic medication such as antidepressants, anxiolytics and antipsychotics.
  7. any medication other than psychotropic medications that is known to cross the blood brain barrier and achieve brain penetrance such that it will alter BOLD signal or lower seizure threshold, such as antibiotics, antihistamines or muscle relaxants.
  8. currently pregnant or breast feeding
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
44 participants (estimated)

Study arms

  • Other
    LIFU/Sham

    double-blind, sham-controlled, crossover study in N=44 individuals with Tobacco Use Disorder

    Device: low intensity focused ultrasound (LIFU)

  • Other
    Sham/LIFU

    double-blind, sham-controlled, crossover study in N=44 individuals with Tobacco Use Disorder

    Device: low intensity focused ultrasound (LIFU)

Interventions

  • Devicelow intensity focused ultrasound (LIFU)

    Low-intensity focused ultrasound (LIFU) provides an energy source with millimeter resolution that can be focused anywhere in the brain safely and effectively for non-invasive and transient neuromodulation. LIFU is an important advance and of great significance for brain-mapping efforts, diagnostics, and therapies in neuroscience and particularly promising for addiction therapy as it provides unprecedented non-surgical access to the brain regardless of depth. Much lower intensities of focused ultrasound (LIFU) are used so that tissue damage does not occur, but neural activity can be modulated. LIFU utilizes acoustic energy at much lower levels to affect tissue by mechanical effects.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    number of adverse events

    Time frame: immediately prior to 1 session LIFU and within 1 hour post LIFU; immediately prior to 1 session sham and with in 1 hour post shamdays

Secondary outcomes

  1. Smoking cue-induced craving

    numerical craving rating scale Score Range: 0-100 (Higher score meaning worse outcome) 0 = No thoughts of Craving 100 = All of your thoughts of craving

    Time frame: immediately prior to 1 session LIFU and within 1 hour post LIFU; immediately prior to 1 session sham and with in 1 hour post sham

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — behavioral and imaging data

Supporting information: Statistical analysis plan, Analytic code

Time frame: data will be available after analysis of primary and secondary outcomes are completed

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Mar 2026, 47 months after the start.

Of 257 non-industry interventional studies with no phase under Tobacco Use Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 51. This study's planned 47 months is above that.

Counting every sponsor, half of 267 studies reached it within 32 months; a quarter within 16 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2023
First posted
May 8, 2024
StartActual
Apr 1, 2022
Primary completionEst.
Mar 31, 2026
CompletionEst.
Mar 31, 2026
Last update
Nov 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06405074
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Responsible party
Sponsor
First posted
May 8, 2024
Start date
Apr 1, 2022
Primary completion
Mar 31, 2026 (estimated)
Completion
Mar 31, 2026 (estimated)
Last update
Nov 20, 2024

Study contacts

Mary R. Lee, MD
Contact
mary.lee3@va.gov
202-745-8000 ext. 58128
Evan Lindeman, BS
Contact
evan.lindeman@va.gov
Mary R Lee, MD
principal investigator · Veterans Affairs Medical Center, Washington DC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion